Drug Trial Radar · NCT05947890
Evaluating the Safety and Immunogenicity of MTBVAC
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
Jan 30, 2024
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- HIV Vaccine Trials NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Biofabri, S.L; Fred Hutchinson Cancer Center
- First posted
- Jul 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
Conditions
- HIV I Infection
- Tuberculosis
Interventions
MTBVACBiological
The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
BCGBiological
The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of unsolicited adverse eventsTime frame: Through study week 48
- Number of solicited adverse eventsTime frame: Through study week 16
- Number of Grade 3 or higher adverse eventsTime frame: Through study week 48
- Number of serious adverse eventsTime frame: Through study week 48
- Frequency and response of MTBVAC-reactive CD4+ cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks 4
- Frequency and response of MTBVAC-reactive CD4+ cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks10
- Frequency and response of MTBVAC-reactive CD8+ T cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks 4
- Frequency and response of MTBVAC-reactive CD8+ T cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks10
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Cape Town - Khayelitsha
Cape Town, South Africa · Recruiting
Durban - Chatsworth
Chatsworth, South Africa · Recruiting
Durban eThekwini
Durban, South Africa · Terminated
Durban - Isipingo
Isipingo, South Africa · Recruiting
Klerksdorp
Klerksdorp, South Africa · Recruiting
Ladysmith
Ladysmith, South Africa · Recruiting
Rustenburg CRS
Rustenburg, South Africa · Terminated
Soshanguve
Soshanguve, South Africa · Terminated
Soweto - Gauteng
Johannesburg, Gauteng, South Africa · Terminated
Johannesburg - CHRU
Westdene, Gauteng, South Africa · Recruiting
Durban - Botha's Hill CRS
Durban, KwaZulu-Natal, South Africa · Recruiting
Durban - Wentworth
Durban, KwaZulu-Natal, South Africa · Terminated
Cape Town - UCTLI
Cape Town, Western Cape, South Africa · Recruiting
Cape Town - Emavundleni
Cape Town, Western Cape, South Africa · Terminated
Cape Town - Groote Schuur
Cape Town, Western Cape, South Africa · Recruiting
Worcester - SATVI
Worcester, Western Cape, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.